Close Menu

Prostate Cancer

News and reporting on prostate cancer.

The PCR-based test analyzes mitochondrial DNA to detect prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and age.

The decision, which enables Medicare reimbursement, is effective for tests administered on or after Dec. 1.

The Royal Oaks, Michigan-based firm anticipates launching the assay — which currently analyzes 214 genes for prostate cancer risk — for research-use-only applications in H2 2020.

The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.

The team will use a combination of genomics, pathology, and computer modeling to identify potential new therapeutic targets of the disease.

The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform. 

For the six-month period ended June 30, the molecular diagnostic company's revenues fell to $10.9 million from $17.2 million in H1 2018.

Australian researchers are studying the prevalence of genetic alterations among men with metastatic prostate cancer, the Financial Review reports.

Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.

The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.